These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 29356172)

  • 1. Therapy response was not altered by HLA-Cw6 status in psoriasis patients treated with secukinumab: a retrospective case series.
    Anzengruber F; Drach M; Maul JT; Kolios AG; Meier B; Navarini AA
    J Eur Acad Dermatol Venereol; 2018 Jul; 32(7):e274-e276. PubMed ID: 29356172
    [No Abstract]   [Full Text] [Related]  

  • 2. Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis: SUPREME study.
    Costanzo A; Bianchi L; Flori ML; Malara G; Stingeni L; Bartezaghi M; Carraro L; Castellino G;
    Br J Dermatol; 2018 Nov; 179(5):1072-1080. PubMed ID: 29704432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human leucocyte antigen-Cw6 as a predictor for clinical response to ustekinumab, an interleukin-12/23 blocker, in Chinese patients with psoriasis: a retrospective analysis.
    Chiu HY; Wang TS; Chan CC; Cheng YP; Lin SJ; Tsai TF
    Br J Dermatol; 2014 Nov; 171(5):1181-8. PubMed ID: 24734995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IL12B (p40) Gene Polymorphisms Contribute to Ustekinumab Response Prediction in Psoriasis.
    Galluzzo M; Boca AN; Botti E; Potenza C; Malara G; Malagoli P; Vesa S; Chimenti S; Buzoianu AD; Talamonti M; Costanzo A
    Dermatology; 2016; 232(2):230-6. PubMed ID: 26678060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HLA-C*06 and response to ustekinumab in Caucasian patients with psoriasis: Outcome and long-term follow-up.
    Talamonti M; Galluzzo M; Chimenti S; Costanzo A
    J Am Acad Dermatol; 2016 Feb; 74(2):374-5. PubMed ID: 26775778
    [No Abstract]   [Full Text] [Related]  

  • 6. Psoriasis pharmacogenetics: HLA-Cw*0602 as a marker of therapeutic response to ustekinumab.
    Raposo I; Carvalho C; Bettencourt A; Da Silva BM; Leite L; Selores M; Torres T
    Eur J Dermatol; 2017 Oct; 27(5):528-530. PubMed ID: 29084639
    [No Abstract]   [Full Text] [Related]  

  • 7. HLA polymorphism among Chinese patients with chronic plaque psoriasis: subgroup analysis.
    Chiu HY; Huang PY; Jee SH; Hu CY; Chou CT; Chang YT; Hwang CY; Tsai TF
    Br J Dermatol; 2012 Feb; 166(2):288-97. PubMed ID: 21985130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HLA-Cw6-positive patients with psoriasis show improved response to methotrexate treatment.
    West J; Ogston S; Berg J; Palmer C; Fleming C; Kumar V; Foerster J
    Clin Exp Dermatol; 2017 Aug; 42(6):651-655. PubMed ID: 28512993
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Morelli M; Galluzzo M; Madonna S; Scarponi C; Scaglione GL; Galluccio T; Andreani M; Pallotta S; Girolomoni G; Bianchi L; Talamonti M; Albanesi C
    Expert Opin Biol Ther; 2021 Feb; 21(2):259-270. PubMed ID: 33297781
    [No Abstract]   [Full Text] [Related]  

  • 10. Role of the HLA-C*06 allele in clinical response to ustekinumab: evidence from real life in a large cohort of European patients.
    Talamonti M; Galluzzo M; van den Reek JM; de Jong EM; Lambert JLW; Malagoli P; Bianchi L; Costanzo A
    Br J Dermatol; 2017 Aug; 177(2):489-496. PubMed ID: 28207934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction between Smoking and HLA-C*06:02 on the Response to Ustekinumab in Psoriasis.
    Svedbom A; Nikamo P; Ståhle M
    J Invest Dermatol; 2020 Aug; 140(8):1653-1656.e1. PubMed ID: 32014510
    [No Abstract]   [Full Text] [Related]  

  • 12. Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab.
    Talamonti M; Botti E; Galluzzo M; Teoli M; Spallone G; Bavetta M; Chimenti S; Costanzo A
    Br J Dermatol; 2013 Aug; 169(2):458-63. PubMed ID: 23521149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased Risk of Psoriasis due to combined effect of HLA-Cw6 and LCE3 risk alleles in Indian population.
    Chandra A; Lahiri A; Senapati S; Basu B; Ghosh S; Mukhopadhyay I; Behra A; Sarkar S; Chatterjee G; Chatterjee R
    Sci Rep; 2016 Apr; 6():24059. PubMed ID: 27048876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Cw6 and late-cornified envelope genotype plays a significant role in anti-tumor necrosis factor response among psoriatic patients.
    Batalla A; Coto E; González-Fernández D; González-Lara L; Gómez J; Santos-Juanes J; Queiro R; Coto-Segura P
    Pharmacogenet Genomics; 2015 Jun; 25(6):313-6. PubMed ID: 25794162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impetigo herpetiformis with IL-36RN mutation successfully treated with secukinumab.
    Kinoshita M; Ogawa Y; Takeichi T; Okamoto T; Osada A; Shimada S; Sugiura K; Akiyama M; Kawamura T; Tsukamoto K
    Eur J Dermatol; 2018 Jun; 28(3):381-382. PubMed ID: 30105995
    [No Abstract]   [Full Text] [Related]  

  • 16. Response to Secukinumab after Treatment Failure with Ustekinumab in 6 Patients with Plaque Psoriasis.
    Morgado-Carrasco D; Riera-Monroig J; Fustà-Novell X; Alsina Gibert M
    Actas Dermosifiliogr (Engl Ed); 2018; 109(6):565-567. PubMed ID: 29169562
    [No Abstract]   [Full Text] [Related]  

  • 17. Secukinumab in multi-failure psoriatic patients: the last hope?
    Magnano M; Loi C; Patrizi A; Sgubbi P; Balestri R; Rech G; Tasin L; Girardelli CR; Conti A; Odorici G; Campanati A; Offidani AM; Bardazzi F
    J Dermatolog Treat; 2018 Sep; 29(6):583-585. PubMed ID: 29334270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical experience of secukinumab in the treatment of erythrodermic psoriasis: a case series.
    Weng HJ; Wang TS; Tsai TF
    Br J Dermatol; 2018 Jun; 178(6):1439-1440. PubMed ID: 29265175
    [No Abstract]   [Full Text] [Related]  

  • 19. Association of HLA-C*06:02 Status With Differential Response to Ustekinumab in Patients With Psoriasis: A Systematic Review and Meta-analysis.
    van Vugt LJ; van den Reek JMPA; Hannink G; Coenen MJH; de Jong EMGJ
    JAMA Dermatol; 2019 Jun; 155(6):708-715. PubMed ID: 30994858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Different Responses to Ustekinumab of Two HLA-Cw6-positive Homozygous Twins with Psoriasis.
    Burlando M; Cozzani E; Campisi C; Di Costanzo A; Parodi A
    Acta Derm Venereol; 2016 Aug; 96(6):858-9. PubMed ID: 26714660
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.